Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.

Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM.

Head Neck. 2019 Feb 13. doi: 10.1002/hed.25634. [Epub ahead of print]

PMID:
30758123
2.

Combined Aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck.

Lee JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, Yang DH, Zhu F, Mehra R, Sharma R, Gaffney SG, Perry EB, Townsend JP, Serebriiskii IG, Golemis EA, Issaeva N, Yarbrough WG, Koo JS, Burtness BA.

Clin Cancer Res. 2019 Feb 12. pii: clincanres.0440.2018. doi: 10.1158/1078-0432.CCR-18-0440. [Epub ahead of print]

PMID:
30755439
3.

Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma.

Lee NCJ, Kelly JR, An Y, Park HS, Judson BL, Burtness BA, Husain ZA.

Cancer. 2019 Feb 12. doi: 10.1002/cncr.32001. [Epub ahead of print]

PMID:
30748002
4.

APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma.

Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP.

Oncogene. 2019 Jan 15. doi: 10.1038/s41388-018-0657-6. [Epub ahead of print]

PMID:
30647454
5.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators.

Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30.

PMID:
30509740
6.

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT.

Lancet. 2019 Jan 5;393(10166):40-50. doi: 10.1016/S0140-6736(18)32779-X. Epub 2018 Nov 15.

PMID:
30449625
7.

Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks.

Kann BH, Aneja S, Loganadane GV, Kelly JR, Smith SM, Decker RH, Yu JB, Park HS, Yarbrough WG, Malhotra A, Burtness BA, Husain ZA.

Sci Rep. 2018 Sep 19;8(1):14036. doi: 10.1038/s41598-018-32441-y.

8.

Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma.

Lee NCJ, Kelly JR, Park HS, An Y, Judson BL, Burtness BA, Husain ZA.

Oral Oncol. 2018 Oct;85:35-39. doi: 10.1016/j.oraloncology.2018.08.001. Epub 2018 Aug 20.

PMID:
30220317
9.

HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes.

Cheraghlou S, Torabi SJ, Husain ZA, Otremba MD, Osborn HA, Mehra S, Yarbrough WG, Burtness BA, Judson BL.

Laryngoscope. 2019 Mar;129(3):684-691. doi: 10.1002/lary.27475. Epub 2018 Aug 27.

PMID:
30151832
10.

Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations.

Morse E, Judson B, Husain Z, Burtness B, Yarbrough WG, Sasaki C, Cheraghlou S, Mehra S.

Otolaryngol Head Neck Surg. 2018 Jul 31:194599818779052. doi: 10.1177/0194599818779052. [Epub ahead of print]

PMID:
30060700
11.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R.

Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29.

PMID:
29955135
12.

National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation.

Morse E, Judson B, Husain Z, Burtness B, Yarbrough W, Sasaki C, Cheraghlou S, Mehra S.

Oral Oncol. 2018 Jul;82:122-130. doi: 10.1016/j.oraloncology.2018.02.010. Epub 2018 May 26.

PMID:
29909886
13.

Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database.

Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL.

Head Neck. 2018 Jul;40(7):1343-1355. doi: 10.1002/hed.24984. Epub 2018 May 13.

PMID:
29756412
14.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

PMID:
29752322
15.

Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer.

Kelly JR, Park HS, An Y, Yarbrough WG, Contessa JN, Decker R, Mehra S, Judson BL, Burtness B, Husain Z.

Oral Oncol. 2018 Apr;79:64-70. doi: 10.1016/j.oraloncology.2018.02.017. Epub 2018 Mar 8.

PMID:
29598952
16.

Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck.

Bhatia AK, Burtness BA, Decker RH.

J Clin Oncol. 2018 May 1;36(13):1269-1271. doi: 10.1200/JCO.2018.77.7987. Epub 2018 Mar 16. No abstract available.

PMID:
29547345
17.

NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.

Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA.

Nat Commun. 2017 Nov 24;8(1):1772. doi: 10.1038/s41467-017-01877-7.

18.

Response.

Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA.

J Natl Cancer Inst. 2018 Apr 1;110(4):433-434. doi: 10.1093/jnci/djx230. No abstract available.

PMID:
29121329
19.

The tumor genome in human immunodeficiency virus-related head and neck cancer: Exploitable targets?

Burtness B.

Cancer. 2018 Jan 1;124(1):14-17. doi: 10.1002/cncr.31059. Epub 2017 Oct 20. No abstract available.

20.

Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.

Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N.

Clin Cancer Res. 2017 Dec 1;23(23):7276-7287. doi: 10.1158/1078-0432.CCR-17-1438. Epub 2017 Sep 15.

21.

Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.

Bhatia A, Burtness B.

Cancers (Basel). 2017 Aug 31;9(9). pii: E113. doi: 10.3390/cancers9090113. Review.

22.

Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).

Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez-Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ.

Cancer. 2017 Dec 1;123(23):4653-4662. doi: 10.1002/cncr.30920. Epub 2017 Aug 7.

23.

Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck.

Parameswaran J, Burtness B.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):969-973. doi: 10.1016/j.ijrobp.2017.03.003. Epub 2017 Jul 10. No abstract available.

PMID:
28721906
24.

Lymph-node-positive cutaneous nonmelanoma skin cancer: A poor-prognosis disease in need of treatment intensification.

Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ.

Ear Nose Throat J. 2017 Jul;96(7):E12-E18.

PMID:
28719713
25.

Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment.

Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S.

Oral Oncol. 2017 Aug;71:129-137. doi: 10.1016/j.oraloncology.2017.06.013. Epub 2017 Jun 23.

PMID:
28688680
26.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

PMID:
28596256
27.

Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival.

Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx042.

PMID:
28521361
28.

Reply to A. Garden et al.

Marur S, Li S, Cmelak A, Burtness B.

J Clin Oncol. 2017 Jun 10;35(17):1970-1971. doi: 10.1200/JCO.2017.72.8279. Epub 2017 Apr 21. No abstract available.

PMID:
28430530
29.

Purpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials.

Marur S, Cmelak AJ, Burtness B.

J Clin Oncol. 2017 Jun 10;35(17):1968-1969. doi: 10.1200/JCO.2017.72.2918. Epub 2017 Apr 21. No abstract available.

PMID:
28430529
30.

The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation.

Lee NCJ, Kelly JR, Park HS, Yarbrough WG, Burtness BA, Husain ZA.

Pract Radiat Oncol. 2017 Sep - Oct;7(5):e317-e321. doi: 10.1016/j.prro.2017.02.004. Epub 2017 Feb 16.

PMID:
28356201
31.

The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.

An Y, Park HS, Kelly JR, Stahl JM, Yarbrough WG, Burtness BA, Contessa JN, Decker RH, Koshy M, Husain ZA.

Cancer. 2017 Jul 15;123(14):2762-2772. doi: 10.1002/cncr.30598. Epub 2017 Mar 21.

32.

TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.

Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N.

Cancer. 2017 May 15;123(10):1778-1790. doi: 10.1002/cncr.30570. Epub 2017 Mar 13.

33.

Comparison of Survival Outcomes Among Human Papillomavirus-Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study.

Kelly JR, Park HS, An Y, Contessa JN, Yarbrough WG, Burtness BA, Decker R, Husain Z.

JAMA Oncol. 2017 Aug 1;3(8):1107-1111. doi: 10.1001/jamaoncol.2016.5769.

34.

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B.

J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.

35.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

36.

Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma.

Baxi SS, Dunn LA, Burtness BA.

Oral Oncol. 2016 Nov;62:147-148. doi: 10.1016/j.oraloncology.2016.10.007. Epub 2016 Oct 21. No abstract available.

PMID:
27776933
37.

Treatment de-intensification strategies for head and neck cancer.

Kelly JR, Husain ZA, Burtness B.

Eur J Cancer. 2016 Nov;68:125-133. doi: 10.1016/j.ejca.2016.09.006. Epub 2016 Oct 15. Review.

38.

A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma.

Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, Yarbrough W, Deshpande H, Mehra S, Kuo P, Decker RH, Burtness BA.

JAMA Oncol. 2017 Mar 1;3(3):358-365. doi: 10.1001/jamaoncol.2016.4581.

PMID:
27737449
39.

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY.

J Clin Oncol. 2016 Nov 10;34(32):3838-3845. doi: 10.1200/JCO.2016.68.1478. Epub 2016 Sep 30.

PMID:
27646946
40.

Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma.

Psyrri A, Rampias T, Burtness B.

JAMA Oncol. 2017 Jan 1;3(1):125. doi: 10.1001/jamaoncol.2016.3409. No abstract available.

PMID:
27607105
41.

EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.

Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA.

Mol Cancer Ther. 2016 Oct;15(10):2486-2497. Epub 2016 Aug 9.

42.

Proposing prognostic thresholds for lymph node yield in clinically lymph node-negative and lymph node-positive cancers of the oral cavity.

Kuo P, Mehra S, Sosa JA, Roman SA, Husain ZA, Burtness BA, Tate JP, Yarbrough WG, Judson BL.

Cancer. 2016 Dec 1;122(23):3624-3631. doi: 10.1002/cncr.30227. Epub 2016 Aug 1.

43.

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB 3rd, Goldberg RM.

J Clin Oncol. 2016 Aug 10;34(23):2736-42. doi: 10.1200/JCO.2015.65.5092. Epub 2016 Jul 5.

44.

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ.

Lancet Oncol. 2016 Jul;17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3. Epub 2016 May 27.

PMID:
27247226
45.

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ.

Lancet Oncol. 2016 Jun;17(6):717-726. doi: 10.1016/S1470-2045(16)00175-3. Epub 2016 May 3.

PMID:
27157491
46.

Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base.

Kuo P, Sosa JA, Burtness BA, Husain ZA, Mehra S, Roman SA, Yarbrough WG, Judson BL.

Cancer. 2016 Jun 15;122(12):1853-60. doi: 10.1002/cncr.29962. Epub 2016 Mar 28.

47.

Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.

Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA.

Am J Clin Oncol. 2017 Aug;40(4):393-398. doi: 10.1097/COC.0000000000000171.

48.

Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Husain ZA, Burtness BA, Decker RH.

J Clin Oncol. 2016 Feb 10;34(5):396-8. doi: 10.1200/JCO.2015.64.7586. Epub 2015 Dec 7. No abstract available.

PMID:
26644528
49.

National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database.

Schwam ZG, Burtness B, Yarbrough WG, Mehra S, Husain Z, Judson BL.

Cancer Med. 2015 Dec;4(12):1828-35. doi: 10.1002/cam4.546. Epub 2015 Oct 16.

50.

Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials.

Bhatia A, Burtness B.

J Clin Oncol. 2015 Oct 10;33(29):3243-50. doi: 10.1200/JCO.2015.61.2358. Epub 2015 Sep 8. Review.

Supplemental Content

Loading ...
Support Center